X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.1875
+0.0003 (0.16%)
Apr 25, 2025, 12:35 PM EDT - Market open
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 143 employees as of December 31, 2024. The number of employees increased by 50 or 53.76% compared to the previous year.
Employees
143
Change (1Y)
50
Growth (1Y)
53.76%
Revenue / Employee
$17,881
Profits / Employee
-$261,888
Market Cap
32.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
XFOR News
- 1 day ago - X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 - GlobeNewsWire
- 1 day ago - X4 Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 1 day ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - GlobeNewsWire